Compare Alcon AG (ALC) vs Global X MSCI Argentina ETF (ARGT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Global X MSCI Argentina ETF — how do they compare? Alcon AG trades at $66.89 (market cap $32.69B), while Global X MSCI Argentina ETF trades at $92.62. The key difference: Alcon AG pays a 0.54% dividend while Global X MSCI Argentina ETF pays none, and Global X MSCI Argentina ETF is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | ARGT | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $92.22 | $102.94 |
52-Week Low | $62.02 | $67.55 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
ARGT trades at $93.99, up 2.78% today, but technical indicators signal a bearish trend with moving averages showing sell pressure. The stock is near resistance at $94, with support at $90. Recent news highlights institutional interest from Stanley Druckenmiller and analyst upgrades citing Argentina's economic reforms and potential valuation upside.
Outlook remains mixed; bullish sentiment from analysts points to a 28% upside if Argentina's turnaround continues, but risks include political volatility and concentrated holdings. The stock offers speculative growth potential amid high macroeconomic uncertainty, requiring careful risk assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Global X MSCI Argentina ETF
ARGT seeks to provide investment results that correspond to the performance of the MSCI All Argentina 25/50 Index. It offers targeted exposure to some of the largest and most liquid companies operating in Argentina.
Read more on ARGT →
